CapWealth Advisors’s Biogen BIIB Stock Holding History

CapWealth Advisors’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-51	Closed	-$16K	–	111
2016 Q3	$16K	Sell	51 -2	-4%	-$592	﹤0.01%	196
2016 Q2	$13K	Hold	53	–	–	﹤0.01%	199
2016 Q1	$14K	Hold	53	–	–	﹤0.01%	215
2015 Q4	$16K	Sell	53 -4	-7%	-$1.15K	﹤0.01%	172
2015 Q3	$17K	Hold	57	–	–	﹤0.01%	170
2015 Q2	$23K	Hold	57	–	–	0.01%	165
2015 Q1	$24K	Buy	+57	New	+$22.5K	0.01%	169
2014 Q4	–	Sell	-57	Closed	-$19K	–	110
2014 Q3	$19K	Hold	57	–	–	﹤0.01%	189
2014 Q2	$18K	Hold	57	–	–	﹤0.01%	197
2014 Q1	$17K	Hold	57	–	–	﹤0.01%	202
2013 Q4	$16K	Hold	57	–	–	﹤0.01%	223
2013 Q3	$14K	Hold	57	–	–	﹤0.01%	271
2013 Q2	$12K	Buy	+57	New	+$12.2K	﹤0.01%	272

Other funds holding BIIB

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

CapWealth Advisors's BIIB Position: Q4 2016 in Review

CapWealth Advisors sold out of Biogen (BIIB) in Q4 2016, closing a stake of 51 shares — an estimated $16K sold.

CapWealth Advisors first reported a position in BIIB in Q2 2013 and held it in 13 quarters. The position peaked at $24K in Q1 2015. 1,026 funds tracked by Wall St. Rank hold BIIB as of Q4 2016.

CapWealth Advisors reported no remaining Biogen position as of Q4 2016 after selling out during the quarter.
CapWealth Advisors sold 51 Biogen shares in Q4 2016, an estimated $16K.
CapWealth Advisors first reported a position in Biogen in Q2 2013 and held it in 13 quarters.
CapWealth Advisors's Biogen position peaked at $24K in Q1 2015.
1,026 funds tracked by Wall St. Rank held Biogen as of Q4 2016.

Based on CapWealth Advisors's 13F filing for Q4 2016, filed 14 Feb 2017.